Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (ZTS) drives innovation in animal health as the global leader in veterinary pharmaceuticals and diagnostics. This news hub provides investors and industry professionals with essential updates on developments impacting companion animal care and livestock health systems.
Access curated press releases and analysis covering product approvals, research breakthroughs, and financial performance. Our repository includes updates on vaccine innovations, parasiticides, diagnostic tools, and strategic partnerships across 100+ markets. Monitor earnings announcements, manufacturing expansions, and regulatory milestones that shape this $80B sector.
Bookmark this page for streamlined tracking of Zoetis' operational progress in developing solutions for pets and farm animals. Return regularly to stay informed about initiatives affecting animal welfare standards and agricultural productivity worldwide.
Zoetis Inc. (NYSE:ZTS) has announced a quarterly dividend of $0.325 per share, set for payment on June 1, 2022. This dividend will be distributed to all stockholders on record as of April 21, 2022. With a strong revenue of $6.7 billion in 2020, Zoetis stands as a leader in animal health, providing innovative solutions worldwide. This financial return reflects Zoetis's commitment to its shareholders and reinforces its robust market position.
Zoetis Inc. (NYSE:ZTS) announced FDA approval for Solensia™, the first injectable monoclonal antibody treatment for feline osteoarthritis (OA) pain. This once-monthly injection targets Nerve Growth Factor (NGF), effectively controlling OA pain and enhancing feline mobility and well-being. Studies show that 77% of cat owners observed improved pain signs in their cats after treatment. With nearly 40% of cats affected by OA, Solensia addresses a crucial need in veterinary care. It is anticipated to be available to veterinarians in the second half of 2022.
Zoetis (NYSE:ZTS) announced its commitment to achieving carbon neutrality in its operations by 2030. The initiative includes transitioning to 100% renewable energy, highlighted by a virtual power purchase agreement with Vesper Energy to supply 33% of its North American operational energy needs. Currently, 9 out of 28 manufacturing sites and several offices are already using 100% renewable electricity. Zoetis aims to enhance energy efficiency and transparency regarding emissions, reinforcing its sustainability leadership in animal health.
Zoetis (NYSE:ZTS) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. CEO Kristin Peck is scheduled to present at 1:30 p.m. ET and will answer questions from analysts. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations, with a replay available afterward. Zoetis is a leading animal health company with a revenue of $6.7 billion in 2020, supporting animal care globally.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Feb. 15, 2022, at 8:30 a.m. (ET) to discuss fourth quarter and full year 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from analysts. Investors can access the live event on the Zoetis website, with a replay available later that day. Zoetis, a leading animal health company, generated $6.7 billion in revenue in 2020 and operates in over 100 countries, focusing on innovation in animal care.
Zoetis Inc. (NYSE:ZTS) has announced a $3.5 billion share repurchase program to enhance shareholder value, extending over multiple years and potentially cancellable. This follows the completion of a previous $2.0 billion buyback program set for 2022. Additionally, the company declared a $0.325 per share dividend for Q1 2022, marking a 30% increase from 2021. These actions reflect Zoetis' strong financial performance and commitment to returning capital to shareholders.
Zoetis reported a strong financial performance for Q3 2021, with revenue of $2.0 billion, an 11% increase year-over-year, and net income of $552 million, up 15%. Adjusted net income rose to $597 million, or $1.25 per diluted share, marking a 14% increase. The company is optimistic, raising its full-year revenue guidance to $7.700 - $7.750 billion and diluted EPS to $4.23 - $4.29. Key growth drivers included strong sales in petcare products and new monoclonal antibodies, despite facing challenges in livestock product sales.
Zoetis Inc. (NYSE:ZTS) announced the appointment of Robert J. Polzer, PhD, as Executive Vice President and President of Research & Development effective January 1, 2022. He succeeds Dr. Catherine Knupp, who plans to retire after leading Zoetis' R&D efforts since the company's inception in 2013. Under her guidance, Zoetis launched over 1,100 new products in five years and established a strong portfolio in animal health. Polzer, previously Senior VP of Global Therapeutics, brings over 20 years of R&D experience and aims to drive continuous innovation in Zoetis' diverse product pipeline.
Zoetis Inc. (NYSE:ZTS) has declared a fourth quarter 2021 dividend of $0.25 per share, payable on December 1, 2021, to stockholders on record as of October 29, 2021. As a leader in animal health, Zoetis generated revenue of $6.7 billion in 2020, supported by a workforce of approximately 11,300 employees. The company focuses on advancing animal care through innovations in medicines, vaccines, and diagnostics globally.
